You may find more results for this query on our sister sites: 360Dx and Precision Oncology News.
Stratose and Paradigm have inked a deal providing Stratose's members access to the PCDx test, which uses NGS technology to identify genomic and proteomic mutations.
Health Net's coverage of Biodesix's proteomic test for non-small cell lung cancer follows similar decisions last month by Aetna and Cigna.
OKP will pay for testing if standard first trimester screening indicates a risk higher than 1:1000 for trisomies 21, 18, or 13.
Aetna is the first major commercial insurer to cover Interpace's ThyGenX and brings the total number of covered lives for it to more than 100 million.
The test differentiates benign thyroid nodules from cancerous ones.
The company has received similar coverage decisions from other payors in recent months.
The decision means that UnitedHealthcare's members will have access to Biodesix's test for advanced NSCLC as a covered benefit.
Personalized medicines haven't been a big part of APMs to date, but the report suggests ways in which payment models might be structured to spur utilization.
About 19 million ACPN members will now have access to Cancer Genetics' cancer diagnostic services through their insurers.
The noninvasive colorectal cancer screening test will now be available to more than one million people in Massachusetts and Rhode Island.
Novavax has begun a phase III trial of its SARS-CoV-2 vaccine, according to the New York Times.
Vox reports that the Trump Administration may limit student visas for individuals from some countries to two years.
The governor of New York says the state will conduct its own review of any SARS-CoV-2 vaccine, NPR reports.
This week in Science: Neanderthal Y chromosomes replaced by Homo sapiens Y chromosomes, and more.